HIV-2 diagnosis and quantification in high-risk patients

AIDS Research and Therapy

Volumn 5, Issue , 2008, Pages

  Chan, Philip A ^a   Wakeman, Sarah E ^a   Flanigan, Timothy ^b   Cu Uvin, Susan ^b   Kojic, Erna ^b   Kantor, Rami ^b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; EMTRICITABINE; NEUROLEPTIC AGENT; RITONAVIR; TENOFOVIR; VIRUS DNA;

ADULT; ANAMNESIS; ARTICLE; CAPE VERDE; CASE REPORT; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DNA DETERMINATION; ENZYME IMMUNOASSAY; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; INFECTION RISK; LABORATORY TEST; MALE; MENTAL DISEASE; METHODOLOGY; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SEXUAL BEHAVIOR; UNITED STATES; VIRUS DETECTION; VIRUS ENCEPHALITIS; VIRUS LOAD; WESTERN BLOTTING; WHITE MATTER;

EID: 51549116114     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-5-18     Document Type: Article

References (45)

1. Schmidt WP Schim VANDERLM Aaby P Whittle H Bakker R Buckner M Dias F White RG Behaviour change and competitive exclusion can explain the diverging HIV-1 and HIV-2 prevalence trends in Guinea-Bissau Epidemiol Infect 2008, 136(4):551-561 10.1017/S0950268807008758 17559692
2. Factsheet C 1998 http://www.cdc.gov/hiv/resources/factsheets/hiv2.htm
3. Owen SM Yang C Spira T Ou CY Pau CP Parekh BS Candal D Kuehl D Kennedy MS Rudolph D Luo W Delatorre N Masciotra S Kalish ML Cowart F Barnett T Lal R McDougal JS Alternative Algorithms for HIV Diagnosis Using Tests that are Licensed in the United States J Clin Microbiol 2008. 18322061
4. DeParle J In a World on the Move, a Tiny Land Strains to Cope The New York Times 2007.
5. Federation for American Immigration Reform http://www.fairus.org/site/ PageServer?pagename=research_research9f8b_sup#legal
6. Delwart EL Orton S Parekh B Dobbs T Clark K Busch MP Two percent of HIV-positive U.S. blood donors are infected with non-subtype B strains AIDS Res Hum Retroviruses 2003, 19(12):1065-1070 10.1089/ 088922203771881149 14709241
7. Loeff Schim van der MF Aaby P Towards a better understanding of the epidemiology of HIV-2 Aids 1999, 13(Suppl A):S69-84 10885765
8. Kanki PJ Travers KU S MB Hsieh CC Marlink RG Gueye NA Siby T Thior I Hernandez-Avila M Sankale JL Slower heterosexual spread of HIV-2 than HIV-1 Lancet 1994, 343(8903):943-946 10.1016/S0140-6736(94)90065-5 7909009
9. Marlink R Kanki P Thior I Travers K Eisen G Siby T Traore I Hsieh CC Dia MC Gueye EH Reduced rate of disease development after HIV-2 infection as compared to HIV-1 Science 1994, 265(5178):1587-1590 10.1126/ science.7915856 7915856
10. Bienaime A Colson P Moreau J Zandotti C Pellissier JF Brouqui P Progressive multifocal leukoencephalopathy in HIV-2-infected patient Aids 2006, 20(9):1342-1343 10.1097/01.aids.0000232249.89404.d6 16816570
11. Moulignier A Lascoux C Bourgarit A HIV type 2 demyelinating encephalomyelitis Clin Infect Dis 2006, 42(11):e89-91 10.1086/503909 16652302
12. Kanki PJ Barin F M'Boup S Allan JS Romet-Lemonne JL Marlink R McLane MF Lee TH Arbeille B Denis F New human T-lymphotropic retrovirus related to simian T-lymphotropic virus type III (STLV-IIIAGM) Science 1986, 232(4747):238-243 10.1126/science.3006256 3006256
13. Ren J Bird LE Chamberlain PP Stewart-Jones GB Stuart DI Stammers DK Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors Proc Natl Acad Sci USA 2002, 99(22):14410-14415 137897 12386343 10.1073/pnas.222366699
14. Witvrouw M Pannecouque C Switzer WM Folks TM De Clercq E Heneine W Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis Antivir Ther 2004, 9(1):57-65 15040537
15. Adje-Toure CA Cheingsong R Garcia-Lerma JG Eholie S Borget MY Bouchez JM Otten RA Maurice C Sassan-Morokro M Ekpini RE Nolan M Chorba T Heneine W Nkengasong JN Antiretroviral therapy in HIV-2-infected patients: Changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire Aids 2003, 17(Suppl 3):S49-54 14565609
16. Desbois D Roquebert B Peytavin G Damond F Collin G Benard A Campa P Matheron S Chene G Brun-Vezinet F Descamps D In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors Antimicrob Agents Chemother 2008, 52(4):1545-1548 2292533 18227188 10.1128/AAC.01284-07
17. Ntemgwa M Brenner BG Oliveira M Moisi D Wainberg MA Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors Antimicrob Agents Chemother 2007, 51(2):604-610 1797771 17116674 10.1128/ AAC.00870-06
18. Rodes B Sheldon J Toro C Jimenez V Alvarez MA Soriano V Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy J Antimicrob Chemother 2006, 57(4):709-713 10.1093/jac/dkl034 16464891
19. Identification of HIV-1 group O infection - Los Angeles county, California, 1996 MMWR Morb Mortal Wkly Rep 1996, 45(26):561-565 9132574
20. Loussert-Ajaka I Ly TD Chaix ML Ingrand D Saragosti S Courouce AM Brun-Vezinet F Simon F HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients Lancet 1994, 343(8910):1393-1394 10.1016/ S0140-6736(94)92524-0 7910884
21. Schable C Zekeng L Pau CP Hu D Kaptue L Gurtler L Dondero T Tsague JM Schochetman G Jaffe H Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infections Lancet 1994, 344(8933):1333-1334 10.1016/S0140-6736(94)90695-5 7968029
22. Zouhair S Roussin-Bretagne S Moreau A Brunet S Laperche S Maniez M Barin F Harzic M Group o human immunodeficiency virus type 1 infection that escaped detection in two immmunoassays J Clin Microbiol 2006, 44(2):662-665 1392651 16455942 10.1128/JCM.44.2.662-665.2006
23. Saville RD Constantine NT Cleghorn FR Jack N Bartholomew C Edwards J Gomez P Blattner WA Fourth-generation enzyme-linked immunosorbent assay for the simultaneous detection of human immunodeficiency virus antigen and antibody J Clin Microbiol 2001, 39(7):2518-2524 88179 11427563 10.1128/JCM.39.7.2518-2524.2001
24. Weber B Orazi B Raineri A Thorstensson R Burgisser P Muhlbacher A Areal C Eiras A Villaescusa R Camacho R Diogo I Roth HJ Zahn I Bartel J Bossi V Piro F Atamasirikul K Permpikul P Webber L Singh S Multicenter evaluation of a new 4th generation HIV screening assay Elecsys HIV combi Clin Lab 2006, 52(9-10):463-473 17078473
25. Yeom JS Jun G Chang Y Sohn MJ Yoo S Kim E Ryu SH Kang HJ Kim YA Ahn SY Cha JE Youn ST Park JW Evaluation of a new fourth generation enzyme-linked immunosorbent assay, the LG HIV Ag-Ab Plus, with a combined HIV p24 antigen and anti-HIV-1/2/O screening test J Virol Methods 2006, 137(2):292-297 10.1016/j.jviromet.2006.07.002 16908076
26. O'Brien TR George JR Epstein JS Holmberg SD Schochetman G Testing for antibodies to human immunodeficiency virus type 2 in the United States MMWR Recomm Rep 1992, 41(RR-12):1-9 1324395
27. Braun P Ehret R Wiesmann F Zabbai F Knickmann M Kuhn R Thamm S Warnat G Knechten H Comparison of four commercial quantitative HIV-1 assays for viral load monitoring in clinical daily routine Clin Chem Lab Med 2007, 45(1):93-99 10.1515/CCLM.2007.008 17243923
28. Damond F Gueudin M Pueyo S Farfara I Robertson DL Descamps D Chene G Matheron S Campa P Brun-Vezinet F Simon F Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infections J Clin Microbiol 2002, 40(10):3654-3659 130845 12354861 10.1128/ JCM.40.10.3654-3659.2002
29. Elbeik T Alvord WG Trichavaroj R de Souza M Dewar R Brown A Chernoff D Michael NL Nassos P Hadley K Ng VL Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5 J Acquir Immune Defic Syndr 2002, 29(4):330-339 11917236
30. Galli R Merrick L Friesenhahn M Ziermann R Comprehensive comparison of the VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 MONITOR 1.5 assays on 1,000 clinical specimens J Clin Virol 2005, 34(4):245-252 10.1016/j.jcv.2004.12.012 16286047
31. Gleaves CA Welle J Campbell M Elbeik T Ng V Taylor PE Kuramoto K Aceituno S Lewalski E Joppa B Sawyer L Schaper C McNairn D Quinn T Multicenter evaluation of the Bayer VERSANT HIV-1 RNA 3.0 assay: analytical and clinical performance J Clin Virol 2002, 25(2):205-216 10.1016/S1386-6532(02)00011-2 12367656
32. Gomes P Palma AC Cabanas J Abecasis A Carvalho AP Ziermann R Diogo I Goncalves F Lobo CS Camacho R Comparison of the COBAS TAQMAN HIV-1 HPS with VERSANT HIV-1 RNA 3.0 assay (bDNA) for plasma RNA quantitation in different HIV-1 subtypes J Virol Methods 2006, 135(2):223-228 10.1016/ j.jviromet.2006.03.018 16675034
33. Berry N Ariyoshi K Jaffar S Sabally S Corrah T Tedder R Whittle H Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection J Hum Virol 1998, 1(7):457-468 10195267
34. Popper SJ Sarr AD Travers KU Gueye-Ndiaye A Mboup S Essex ME Kanki PJ Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2 J Infect Dis 1999, 180(4):1116-1121 10.1086/315010 10479138
35. Ruelle J Mukadi BK Schutten M Goubau P Quantitative real-time PCR on Lightcycler for the detection of human immunodeficiency virus type 2 (HIV-2) J Virol Methods 2004, 117(1):67-74 10.1016/ j.jviromet.2003.12.006 15019261
36. Rodes B Sheldon J Toro C Cuevas L Perez-Pastrana E Herrera I Soriano V Quantitative detection of plasma human immunodeficiency virus type 2 subtype A RNA by the Nuclisens EasyQ Assay (version 1.1) J Clin Microbiol 2007, 45(1):88-92 1828987 17093034 10.1128/JCM.01613-06
37. Roche Summary Insert: AMPLICOR RT-PCR Version 1.5
38. Schappert J Wians FH Jr Schiff E Smalley D Gambardella R Lee WM Wu J Keiser P Peterson D De Medina M Baker L Preisel-Simmons B Multicenter evaluation of the Bayer ADVIA Centaur HIV 1/O/2 enhanced (EHIV) assay Clin Chim Acta 2006, 372(1-2):158-166 10.1016/j.cca.2006.04.017 16769045
39. Mulder J McKinney N Christopherson C Sninsky J Greenfield L Kwok S Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection J Clin Microbiol 1994, 32(2):292-300 263027 8150937
40. Nolte FS Boysza J Thurmond C Clark WS Lennox JL Clinical comparison of an enhanced-sensitivity branched-DNA assay and reverse transcription-PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma J Clin Microbiol 1998, 36(3):716-720 104614 9508301
41. Pachl C Todd JA Kern DG Sheridan PJ Fong SJ Stempien M Hoo B Besemer D Yeghiazarian T Irvine B Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8(5):446-454 7697440
42. Bayer Summary Insert: Versant HIV-1 RNA 3.0
43. van Gemen B Kievits T Nara P Huisman HG Jurriaans S Goudsmit J Lens P Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification Aids 1993, 7(Suppl 2):S107-110 8161439
44. Schumacher W Frick E Kauselmann M Maier-Hoyle V Vliet van der R Babiel R Fully automated quantification of human immunodeficiency virus (HIV) type 1 RNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system J Clin Virol 2007, 38(4):304-312 10.1016/j.jcv.2006.12.022 17329164
45. Gueudin M Plantier JC Lemee V Schmitt MP Chartier L Bourlet T Ruffault A Damond F Vray M Simon F Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes J Acquir Immune Defic Syndr 2007, 44(5):500-505 10.1097/QAI.0b013e31803260df 17259908